
    
      This open-label, single arm study will evaluate the efficacy and safety of chidamide in
      combination with cyclophosphamide, doxorubicin, vincristine, and prednisolone or prednisone
      (CHOP) chemotherapy in previously untreated subjects with angioimmunoblastic T cell lymphoma.
      Subjects will receive 6 cycles of Chidamide 20mg, day 1,4,8,11, orally (PO) every 21 days, in
      addition to 6 cycles of CHOP chemotherapy IV every 21 days.
    
  